Revolution Medicines (RVMD) Assets Average (2020 - 2026)

Revolution Medicines' Assets Average history runs 7 years deep, the most recent figure standing at $2.3 billion for Q1 2026.

• On a quarterly basis, Assets Average fell 6.41% year-over-year to $2.3 billion in Q1 2026; TTM through Mar 2026 was $2.3 billion, a 6.41% decrease from a year earlier, with the FY2025 full-year figure at $2.5 billion, up 6.34% from the prior year.
• Assets Average steadied at $2.3 billion in Q1 2026 per RVMD's latest filing, from $2.3 billion in the prior quarter.
• Across five years, Assets Average topped out at $2.5 billion in Q1 2025 and bottomed at $657.8 million in Q2 2022.
• The 5-year median for Assets Average is $1.1 billion (2023), against an average of $1.5 billion.
• Across the five-year window, Assets Average fell 17.03% in 2022 and surged 157.38% in 2025, its largest moves.
• Year by year, Assets Average stood at $818.9 million in 2022, then jumped by 85.97% to $1.5 billion in 2023, then soared by 41.87% to $2.2 billion in 2024, then climbed by 6.6% to $2.3 billion in 2025, then climbed by 0.04% to $2.3 billion in 2026.
• Per Business Quant, the three latest RVMD Assets Average figures stand at $2.3 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.3 billion (Q3 2025).